Literature DB >> 27079494

N-Methyl-D-Aspartate Receptors, Ketamine, and Rett Syndrome: Something Special on the Road to Treatments?

David M Katz1, Frank S Menniti2, Robert J Mather3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27079494      PMCID： PMC4924879          DOI： 10.1016/j.biopsych.2016.03.1045

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  9 in total

1.  Cell-Specific Regulation of N-Methyl-D-Aspartate Receptor Maturation by Mecp2 in Cortical Circuits.

Authors:  Susanna B Mierau; Annarita Patrizi; Takao K Hensch; Michela Fagiolini
Journal:  Biol Psychiatry       Date:  2015-06-05       Impact factor: 13.382

2.  NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex.

Authors:  Min Wang; Yang Yang; Ching-Jung Wang; Nao J Gamo; Lu E Jin; James A Mazer; John H Morrison; Xiao-Jing Wang; Amy F T Arnsten
Journal:  Neuron       Date:  2013-02-20       Impact factor: 17.173

3.  Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment.

Authors:  Miriam Kron; C James Howell; Ian T Adams; Michael Ransbottom; Diana Christian; Michael Ogier; David M Katz
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

4.  NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2.

Authors:  Severine Durand; Annarita Patrizi; Kathleen B Quast; Lea Hachigian; Roman Pavlyuk; Alka Saxena; Piero Carninci; Takao K Hensch; Michela Fagiolini
Journal:  Neuron       Date:  2012-12-20       Impact factor: 17.173

5.  Reversal of neurological defects in a mouse model of Rett syndrome.

Authors:  Jacky Guy; Jian Gan; Jim Selfridge; Stuart Cobb; Adrian Bird
Journal:  Science       Date:  2007-02-08       Impact factor: 47.728

6.  Chronic Administration of the N-Methyl-D-Aspartate Receptor Antagonist Ketamine Improves Rett Syndrome Phenotype.

Authors:  Annarita Patrizi; Nathalie Picard; Alex Joseph Simon; Georgia Gunner; Eleonora Centofante; Nick Arthur Andrews; Michela Fagiolini
Journal:  Biol Psychiatry       Date:  2015-08-24       Impact factor: 13.382

7.  Changing subunit composition of heteromeric NMDA receptors during development of rat cortex.

Authors:  M Sheng; J Cummings; L A Roldan; Y N Jan; L Y Jan
Journal:  Nature       Date:  1994-03-10       Impact factor: 49.962

8.  Use of ketamine during procedural sedation: indications, controversies, and side effects.

Authors:  Tonya Jolly; Heather S McLean
Journal:  J Infus Nurs       Date:  2012 Nov-Dec

Review 9.  Rett Syndrome: Crossing the Threshold to Clinical Translation.

Authors:  David M Katz; Adrian Bird; Monica Coenraads; Steven J Gray; Debashish U Menon; Benjamin D Philpot; Daniel C Tarquinio
Journal:  Trends Neurosci       Date:  2016-02       Impact factor: 13.837
  9 in total
  10 in total

1.  The Pathophysiology of Rett Syndrome With a Focus on Breathing Dysfunctions.

Authors:  Jan-Marino Ramirez; Marlusa Karlen-Amarante; Jia-Der Ju Wang; Nicholas E Bush; Michael S Carroll; Debra E Weese-Mayer; Alyssa Huff
Journal:  Physiology (Bethesda)       Date:  2020-11-01

2.  Common Pathophysiology in Multiple Mouse Models of Pitt-Hopkins Syndrome.

Authors:  Courtney Thaxton; Alexander D Kloth; Ellen P Clark; Sheryl S Moy; Raymond A Chitwood; Benjamin D Philpot
Journal:  J Neurosci       Date:  2017-12-08       Impact factor: 6.167

3.  Clinical and Preclinical Evidence for M1 Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett Syndrome.

Authors:  Mackenzie Smith; Bright Arthur; Jakub Cikowski; Calista Holt; Sonia Gonzalez; Nicole M Fisher; Sheryl Anne D Vermudez; Craig W Lindsley; Colleen M Niswender; Rocco G Gogliotti
Journal:  Neurotherapeutics       Date:  2022-06-07       Impact factor: 6.088

Review 4.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

Review 5.  Treating Rett syndrome: from mouse models to human therapies.

Authors:  Neeti Vashi; Monica J Justice
Journal:  Mamm Genome       Date:  2019-02-28       Impact factor: 2.957

6.  Rett and Rett-like syndrome: Expanding the genetic spectrum to KIF1A and GRIN1 gene.

Authors:  Jiaping Wang; Qingping Zhang; Yan Chen; Shujie Yu; Xiru Wu; Xinhua Bao
Journal:  Mol Genet Genomic Med       Date:  2019-09-11       Impact factor: 2.183

7.  Association of CaMK2A and MeCP2 signaling pathways with cognitive ability in adolescents.

Authors:  Li-Ching Lee; Ming-Tsan Su; Hsing-Ying Huang; Ying-Chun Cho; Ting-Kuang Yeh; Chun-Yen Chang
Journal:  Mol Brain       Date:  2021-10-04       Impact factor: 4.041

8.  Autistic-like social deficits in hippocampal MeCP2 knockdown rat models are rescued by ketamine.

Authors:  Miyeon Choi; Seung Yeon Ko; Jee Young Seo; Do Gyeong Kim; Huiju Lee; Heekyoung Chung; Hyeon Son
Journal:  BMB Rep       Date:  2022-05       Impact factor: 5.041

Review 9.  Proteomic and transcriptional changes associated with MeCP2 dysfunction reveal nodes for therapeutic intervention in Rett syndrome.

Authors:  Ketan Marballi; Jessica L MacDonald
Journal:  Neurochem Int       Date:  2021-05-26       Impact factor: 4.297

10.  Dendrimer-conjugated glutaminase inhibitor selectively targets microglial glutaminase in a mouse model of Rett syndrome.

Authors:  Elizabeth Smith Khoury; Anjali Sharma; Rajasekhar R Ramireddy; Ajit G Thomas; Jesse Alt; Amanda Fowler; Rana Rais; Takashi Tsukamoto; Mary E Blue; Barbara Slusher; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  Theranostics       Date:  2020-04-27       Impact factor: 11.556
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.